ASLN Aslan Pharmaceuticals Ltd ADR

$1.75
$-0.09 (-4.89%)

ASLN Stock Analysis Overview

What this means: Aslan Pharmaceuticals Ltd ADR (ASLN) gets an Overall Rank of 57, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. ASLN's 57 means that it ranks higher than 57% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Aslan Pharmaceuticals Ltd ADR (ASLN) Analyst Forecast

Next 12 months ➝MEAN$5.50+214.29%HIGH$6.00+242.86%LOW$5.00+185.71%Current Price$1.7552-week High$8.1852-week Low$0.35
  • Last Price$1.75
  • Previous Close$1.84
  • Change $-0.09
  • Open$1.85
  • Volume62,568
  • Avg. Volume (100-day)190,444
  • Market Capitalization$66M
  • Days Range $1.70 - $1.85
  • 52-week Range $0.35 - $8.18
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS-1.41
  • Earnings Date10/29/2020
  • SectorHealthcare
  • IndustryBiotechnology
  • Avg. Analyst Rec.
  • Beta0.902
  • PEG Ratio
ASLAN Pharmaceuticals Ltd is a clinical-stage immunology and oncology-focused biopharmaceutical company. It is engaged in developing treatments to transform the lives of patients. The company has a clinical portfolio comprised of a first in class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and a small molecule inhibitor targeting oncology.